The company's AI-assisted platform, FidoCure, has already shown promising results. In a test with pharmaceutical company Eisai, dogs with a type of cancer genetically similar to human breast cancer were treated with a drug called Eribulin, resulting in survival of over 120 days. This outcome was promising enough for the National Institutes of Health to consider the drug for trials in human patients.
Key takeaways:
- A new study reveals a high degree of genetic overlap between human and dog cancers, potentially speeding up the development of new cancer treatments for both species.
- The study was conducted by a company that uses genetic information and AI to find biologic cancer treatments, with ambitions to use this technology to accelerate cancer research.
- Dogs are considered a good source for testing cancer protocols due to their complexity, and the genes that overlap with human genes are those that scientists are already focused on treating.
- The company's AI-assisted platform, FidoCure, has already shown promising results in the lab, with dogs treated with a drug called Eribulin surviving over 120 days, leading to the NIH picking up the drug for trials in human patients.